The European Medicines Agency's Paediatric Committee (PDCO) published the minutes of its 24-27 March 2026 meeting on 8 May 2026, detailing decisions on paediatric investigation plans (PIPs), waivers, and deferrals for several medicinal products. The document outlines regulatory obligations for pharmaceutical companies developing treatments for children across oncology, neurology, and rare diseases.
The PDCO reviewed applications for PIPs, granting full or partial waivers for some products where paediatric studies lack therapeutic benefit or feasibility. Deferrals were also granted, allowing companies to submit paediatric data after completing adult studies. These decisions balance the need for paediatric data with avoiding unnecessary trials in children.
Policy orientations and trade-offs
Waivers reduce regulatory burden for developers but may delay paediatric data generation. Deferrals offer flexibility for companies to prioritise adult studies, but risk postponing paediatric evidence. The committee also discussed age-appropriate formulations, which increase development costs but improve treatment adherence in children.
Impact on stakeholders
Pharmaceutical companies face direct impacts: those with PIP approvals must commit to paediatric studies, increasing R&D costs and timelines. Companies granted waivers or deferrals gain regulatory relief but may face later obligations. Paediatric patients and healthcare providers benefit from eventual safety and efficacy data, though deferrals mean delayed access. EU regulatory bodies gain clarity on paediatric development pipelines, supporting public health planning.
Expected institutional follow-up
Companies must adhere to agreed PIPs, with progress reports due to the PDCO. The EMA will monitor compliance and may impose penalties for non-fulfilment. The minutes also note ongoing harmonisation efforts with the European Commission on paediatric regulation updates. The next PDCO meeting is scheduled for May 2026, with minutes to be published subsequently.